AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00541957 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Medication prescribed by PCP
Description: Can include any antidepressant medication
Study NCT02947451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
Study NCT03671863 — intervention group
Intervention type: OTHER
Intervention: Invasive analysis (caryotype, CGH array)
Description: Invasive analysis (caryotype, CGH array)
Study NCT03671863 — intervention group
Intervention type: OTHER
Intervention: Prenatal management
Description: Prenatal management
Study NCT03340740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 1 MG/ML
Description: Cetirizine oral suspension
Study NCT03340740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Similar-appearing liquid to cetirizine oral suspension
Study NCT02752308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
Study NCT02752308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
Study NCT02752308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilute epinephrine injection
Description: Injection of 1/100000 epinephrine solution along all incision lines
Study NCT02487446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
Study NCT02613507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02487446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
Study NCT02487446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (umeclidinium/vilanterol)
Description: Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
Study NCT02487446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (QVA149)
Description: Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Study NCT00988585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA 600
Description: EPA 600 mg/day for 6 weeks
Study NCT00988585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA 1800
Description: 1800 mg/day for 6 weeks
Study NCT00988585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 600 mg/day for 6 weeks
Study NCT00988585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: 600 mg/day for 6 weeks
Study NCT03868319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung protective ventilation strategy
Description: low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
Study NCT03868319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonprotective ventilation
Description: large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
Study NCT02613507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT00995358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptide
Description: Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
Study NCT04143607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT06689683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave lithotripsy
Description: SWL works on the principle of focusing on the calculus using fluoroscopy. There has yet to be a consensus on the optimal frequency of fluoroscopic monitoring in the literature.
Study NCT02752308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
Study NCT02752308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dextrose plus sodium chloride.
Description: Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
Study NCT06694909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS + PNS with action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
Study NCT03018665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral，0.85g，twice a day in three months
Study NCT06694909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS + sham PNS with action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
Study NCT06694909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + PNS without action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
Study NCT02752308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine and atropine
Description: Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
Study NCT04143607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ASK120067
Description: Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT02028039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 75 mg orally twice daily for 4 weeks.
Study NCT02752308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypospadias repair
Description: Surgical repair of hypospadias, using tubularized incised plate technique
Study NCT03002376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810
Description: REGN2810 treatment
Study NCT02779387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Study NCT02393651 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
Study NCT02028039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up Visit/Call
Description: Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
Study NCT01566435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Study NCT01566435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01566435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study NCT01566435 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Study NCT01566435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT01566435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
Study NCT02940444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT02940444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study NCT03005366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vernakalant
Description: Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
Study NCT03005366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide
Description: 2 mg /kg (max 150 mg) intravenously over 10 minutes.
Study NCT03098485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 5 days of levofloxacin administration
Study NCT03098485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 5 days of azithromycin administration
Study NCT06694909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS + PNS with action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
Study NCT06694909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS + sham PNS with action observation
Description: tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
Study NCT03098485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefpodoxime
Description: 5 days of cefpodoxime administration
Study NCT01157429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
Study NCT01157429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
Study NCT01157429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: 12-session CBT protocol, called Youth PTSD Treatment.
Study NCT01157429 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: 12-session CBT protocol, called Youth PTSD Treatment.
Study NCT03000127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel 1 % Topical Gel
Description: testosterone gel
Study NCT03000127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo gel
Study NCT00095927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine
Description: Given subcutaneously
Study NCT00095927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT00095927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02393651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
Study NCT04081012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
Study NCT00095927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT01402258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-administrated CBT-Treatment
Description: This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
Study NCT04081012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
Study NCT00095927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03983655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Low Intensity TMS
Description: 125 hz, 10 gauss, 2 times daily for 6 monts
Study NCT03983655 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Frequency Low Intensity TMS
Description: 125 hz, 10 gauss, 2 times daily for 6 monts
Study NCT05019807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WhatsApp group
Description: Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.
Study NCT05019807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
Study NCT01395537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC
Description: Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
Study NCT04879381 — intervention group
Intervention type: OTHER
Intervention: Sputum samples
Description: During consultation, one expectoration will be performed.
Study NCT00691782 — intervention group
Intervention type: OTHER
Intervention: Survey of exercise practices
Description: detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
Study NCT04548258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric intraoral weilding
Description: weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
Study NCT04548258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: casting
Description: casting metal framework
Study NCT03928405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises with Nintendo Wii virtual reality device
Description: In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
Study NCT00095927 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: Given once daily for 4 weeks and then twice daily for 2 weeks.
Study NCT00779519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP435
Study NCT00779519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01410019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gene transfer
Description: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
Study NCT00095927 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Given once daily for 4 weeks and then twice daily for 2 weeks.
Study NCT01395537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
Study NCT01395537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
Study NCT01580722 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: early reconstruction
Description: patients underwent \< 8 weeks reconstruction after injury
Study NCT01580722 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: delay reconstruction
Description: patients underwent > 8 weeks reconstruction after injury
Study NCT03164356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance monitor
Description: Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
Study NCT04423367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib/dexamethasone
Description: Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.
Study NCT03665857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a multicomponent intervention
Description: 1. School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~2. Monitoring of students' weight and height Students will be monitored their weight and height monthly.~3. Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~4. Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~5. The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors.
Study NCT03573102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: SGLT2 inhibitor 10 mg/day
Study NCT03573102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Description: ACE inhibitor once daily
Study NCT03573102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: ACE inhibitor once daily
Study NCT04695587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 123 MIBG scintigraphy testing
Description: 123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
Study NCT04695587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MSNA
Description: MSNA in subacute phase and 12 months after the acute episode
Study NCT04695587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABPM
Description: ABPM in subacute phase and 12 months after the acute episode
Study NCT00641147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given PO
Study NCT00641147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04770818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Brostrum procedure with Internal Brace Augmentation
Description: Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability with InternalBrace augmentation.
Study NCT04770818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Brostrum procedure
Description: Open, anatomic repair of the anterior talofibular and calcaneofibular ligaments for lateral ankle stability
Study NCT01048203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABR-215050
Description: 1 mg ABR-215050
Study NCT01373853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lens Fragmentation by means of a femtosecondlaser
Description: In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.